Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis
June 08, 2021 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, June 08, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate...
Kiniksa Outlines Next Steps for the Development of Mavrilimumab
June 08, 2021 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Defined regulatory pathway for Phase 3 clinical development of mavrilimumab in multiple indications - - Continued development in COVID-19-related ARDS represents fastest path to potential...
Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference
June 01, 2021 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, June 01, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Goldman Sachs 42nd Annual Global Healthcare...
Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
May 04, 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- ARCALYST® (rilonacept) launched as the first and only FDA-approved therapy for recurrent pericarditis -- Mavrilimumab Phase 2 severe COVID-19 data demonstrated a reduction in mechanical ventilation...
Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404
May 04, 2021 07:59 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Highest dose cohorts confirm and extend previously-reported 3 mg/kg IV cohort data -- 10 mg/kg IV dose provides full receptor occupancy through Day 71 and complete suppression of TDAR after KLH...
Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients
April 12, 2021 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Primary endpoint achieved: the proportion of patients alive and free of mechanical ventilation at Day 29 was 12.3 percentage points higher with mavrilimumab versus placebo (p=0.1224 met predefined...
Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis
April 01, 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis –- ARCALYST now available on prescription basis in the U.S. –- Kiniksa One Connect™ program provides ongoing patient...
Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis
March 18, 2021 16:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
- ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis -- Commercial launch expected in April 2021 -- Kiniksa launches Kiniksa One Connect™ patient support program --...
Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis
March 02, 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, March 02, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate...
Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity
February 23, 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Strong execution across pipeline of immune-modulating assets throughout 2020 enables multiple milestones in 2021 -- Rilonacept in recurrent pericarditis granted priority review, with PDUFA goal date...